• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Traws Pharma, Inc. - Common Stock (NQ:TRAW)

    1.200 -0.030 (-2.44%)
    Streaming Delayed Price Updated: 9:38 AM EDT, Apr 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 56,163
    Open 1.230
    Bid (Size) 1.190 (100)
    Ask (Size) 1.210 (300)
    Prev. Close 1.230
    Today's Range 1.170 - 1.275
    52wk Range 0.9801 - 3.265
    Shares Outstanding 5,564,315
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold ↗
    Traws Pharma reports 2025 net income but stock falls on dilutive $60M PIPE financing. Focus remains on clinical trials for its influenza and COVID-19 antiviral candidates. 
    Via Chartmill
    Topics Earnings
    News headline image
    Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
    From Traws Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -9.8%
    -9.8%
    1 Month
    -43.1%
    -43.1%
    3 Month
    -32.2%
    -32.2%
    6 Month
    -57.6%
    -57.6%
    1 Year
    -43.7%
    -43.7%

    More News

    Read More
    News headline image
    Traws Pharma Announces Up to $60 Million Private Placement Financing
    From Traws Pharma, Inc.
    Via GlobeNewswire
    Top stock movements in today's session. ↗
    Via Chartmill
    TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
    Via Stocktwits
    Gapping stocks in Thursday's session ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
    From Traws Pharma, Inc.
    Via GlobeNewswire
    Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Which stocks are moving on Friday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
    From Traws Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
    Via Investor Brand Network
    News headline image
    Annovis Appoints Mark Guerin as Chief Financial Officer
    From Annovis Bio Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
    From Traws Pharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Traws Pharma, Inc. - Common Stock publicly traded?
    Yes, Traws Pharma, Inc. - Common Stock is publicly traded.
    What exchange does Traws Pharma, Inc. - Common Stock trade on?
    Traws Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Traws Pharma, Inc. - Common Stock?
    The ticker symbol for Traws Pharma, Inc. - Common Stock is TRAW on the Nasdaq Stock Market
    What is the current price of Traws Pharma, Inc. - Common Stock?
    The current price of Traws Pharma, Inc. - Common Stock is 1.200
    When was Traws Pharma, Inc. - Common Stock last traded?
    The last trade of Traws Pharma, Inc. - Common Stock was at 04/16/26 09:38 AM ET
    What is the market capitalization of Traws Pharma, Inc. - Common Stock?
    The market capitalization of Traws Pharma, Inc. - Common Stock is 6.68M
    How many shares of Traws Pharma, Inc. - Common Stock are outstanding?
    Traws Pharma, Inc. - Common Stock has 7M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.